Oxaliplatin for Children With Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine the pediatric neoplastic response to chemotherapy proposed and evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1 expression analysis.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01558453
Study type	Interventional
Source	Hospital Santa Marcelina
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03690869` - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	Phase 1/Phase 2
Active, not recruiting	`NCT04238819` - A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma	Phase 1/Phase 2
Recruiting	`NCT05468359` - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	Phase 1/Phase 2
Withdrawn	`NCT03443622` - Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	Phase 1
Recruiting	`NCT06375564` - Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression	Phase 1
Terminated	`NCT02164097` - ODSH + ICE Chemotherapy in Pediatric Solid Tumors	Phase 1
Recruiting	`NCT05963386` - Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors	Phase 1
Completed	`NCT00110357` - Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors	Phase 1